Published in 2026. This report examines developments from 2024–2026.
Executive summary
An evergreen landscape report of 14 verified AI companies in Healthcare covered on Brel Digital, grounded in company profile sources already on file rather than market-size forecasts. Companies referenced: Abridge, Absci, Aidoc, Akasa, AliveCor, Ambience Healthcare, Anumana, Artisight, Atomwise, Beacon Biosignals, BenchSci, Biofourmis, BostonGene, Butterfly Network.
Methodology
This report is generated from published Brel Digital company profiles in the Healthcare sector. Each cited company has an official or supporting URL on file. The report does not invent funding amounts, customer logos, revenue figures, or unaudited performance claims. Coverage reflects Brel’s editorial inventory as of 2026-07-12.
Sector coverage on Brel
Brel currently tracks at least 14 published companies in Healthcare with official sources on file for this report sample. The sample below is alphabetical and is not a ranking.
Company examples
- Abridge — Abridge is a leading enterprise ambient documentation vendor scaling into rural health systems — WVU Medicine's March 2026 expansion to 2,800 clinicians demonstrates clinician-driven adoption beyond initial Epic-centric pilots.
- Absci — Absci's 2025 transition to clinical-stage operations with AI-designed ABS-101 dosing in Phase 1 is a concrete milestone for Generative AI drug creation — moving from partnership headlines to investigational therapies with cleared…
- Aidoc — Aidoc's June 2026 FDA Breakthrough Device Designation for First Read — AI that drafts radiology report text from chest X-rays — signals clinical AI moving from triage alerts into generative reporting workflows…
- Akasa — Akasa extends generative AI from autonomous medical coding into Clinical Documentation integrity at Cleveland Clinic — a October 2025 partnership showing health systems treat mid-cycle GenAI as margin-protection infrastructure, not experimental chatbots.
- AliveCor — AliveCor's January 2026 FDA clearance adds five cardiac determinations to KAI 12L — bringing total to 39 and reinforcing handheld 12-lead ECG as a reimbursed outpatient modality after CMS payment approval in…
- Ambience Healthcare — Ambience Healthcare extends ambient AI beyond scribing into coding-aware documentation and revenue integrity — a 2026 KLAS CHIME Trailblazer recognition signals health-system buyer validation at enterprise scale.
- Anumana — Anumana's April 2026 FDA clearance for ECG-AI cardiac amyloidosis detection adds a third cleared algorithm to its portfolio — turning routine ECGs into multi-condition screening tools with CPT reimbursement pathways already established…
- Artisight — Artisight is scaling enterprise smart-hospital deployments with defined KPIs — MetroHealth's May 2026 selection across nearly 500 patient rooms tests whether ambient inpatient AI can unify virtual nursing, fall monitoring, and throughput…
Linked founders
Founder profiles in this sector include: James Min MD, Joseph Mossel, Jeff Elton PhD, Manuel Marina Breysse, Markus Holzer, Ankit Jain.
Linked products
Verified product records include: AI Management System (AIMS), Ezra AI offering, Ambience Healthcare AI offering, K Health AI offering, Abridge AI offering, Biofourmis AI offering.
Linked technologies
Most frequent technology tags among sampled companies: Healthcare Analytics, Deep Learning, Machine Learning, Predictive Analytics, Clinical Documentation, Large Language Models (LLMs).
Linked use cases
Most frequent use-case tags among sampled companies: Medical Imaging, Ambient Scribing, Clinical Documentation, AI Governance & Compliance, Workflow Automation, Conversational AI.
Limitations
This landscape is limited to companies already published on Brel Digital and does not claim to be a complete market map. Figures such as valuation, ARR, or detection rates are omitted unless independently verified on the cited company sources.
Conclusion
Readers evaluating AI vendors in Healthcare should start from the linked company, product, founder, and technology pages and confirm current details against each company’s official materials.